FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, in particular to a method for producing a therapeutically active fusion protein, comprising a moiety for targeted interaction with a tumour and at least one immunomodulating moiety that counteracts the immune tolerance of a cancer cell, as well as a preparation for the treatment of epithelial forms of cancer, comprising an effective amount of homogeneous therapeutically active fusion proteins obtained by said method. Also disclosed is a nucleic acid encoding a fusion protein, comprising a moiety for targeted interaction with a tumour and at least one immunomodulating moiety. Invention also relates to an expression vector comprising the aforementioned nucleic acid.
EFFECT: invention makes it possible to efficiently obtain a therapeutically active fusion protein.
11 cl, 64 dwg, 6 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED IMMUNOMODULATORY PROTEINS AND METHODS FOR PRODUCTION THEREOF | 2014 |
|
RU2698975C2 |
| TARGETED/IMMUNOMODULATING FUSION PROTEINS AND METHODS FOR THEIR OBTAINING | 2013 |
|
RU2636342C2 |
| TARGETED TGF BETA INHIBITION | 2015 |
|
RU2752424C2 |
| BLOCKING ANTI-Dkk-1 ANTIBODIES AND APPLICATIONS THEREOF | 2010 |
|
RU2548817C2 |
| ANTI-PD-1 ANTIBODIES, METHOD FOR THEIR PRODUCTION, AND METHOD OF APPLICATION | 2016 |
|
RU2656181C1 |
| ANTIBODIES-ANTAGONISTS AGAINST Notch3 AND THEIR APPLICATION FOR PREVENTION AND TREATMENT OF Notch3-RELATED DISEASES | 2007 |
|
RU2493167C2 |
| ANTIBODIES TO INTERLEUKIN-1ALPHA, AND APPLICATION METHODS THEREOF | 2013 |
|
RU2666915C2 |
| ANTI-PTK7 ANTIBODY-DRUG CONJUGATES | 2015 |
|
RU2708075C2 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES | 2010 |
|
RU2569109C2 |
